 |
 |
|
 |
|
Welcome to edition #1 of the SWOG Update.
For all members and friends of the Southwest Oncology Group, the SWOG Update will keep you informed of what's happening with the Group. News to report? Send it to communications@swog.org.
|
|
|
|
 |
| |
 |
|
 |
|
Why we do what we do
Our mission is straightforward: to make progress in the prevention and cure of cancer through clinical research. Our research objectives define how we work to accomplish our mission.
[more]
|
|
|
|
 |
 |
|
|
|
You, your colleagues, and your cooperative group in the media ...
|
|
|
|
|
|
 |
|
|
|
Study Updates
Newly activated S0819 will test adding new drug to a standard lung cancer therapy
SWOG’s newest study, and the first phase III study to be rolled out via the Group’s fast-track SWAT process (see SWAT story), is activated as of July 15, 2009 (though as of this writing it was still awaiting its first site IRB approval).
This study will compare outcomes for lung cancer patients given an accepted standard treatment (either carboplatin and paclitaxel or carboplatin, pacitaxel, and bevacizumab) and patients given the same treatment plus an additional drug – cetuximab.
The endpoints to be compared are overall survival (OS) with or without cetuximab in the entire study population and progression-free survival (PFS) in EGFR FISH-positive patients.
This intergroup study, titled "A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)," builds on S0342 and S0536.
Study coordinators are Roy S. Herbst, M.D., Ph.D, Edward Kim, M.D., David R. Gandara, M.D., and Fred R. Hirsch, M.D., Ph.D.
All SWOG member and affiliate institutions, Community Clinical Oncology Programs (CCOPs), and other U.S. institutions within the NCI’s Clinical Trials Support Unit (CTSU) are eligible to participate. Full board review is required for initial activation, should your institution choose to participate.
Cancer patients who have been diagnosed with Stage IV, advanced primary non-small cell lung cancer or recurrent disease after previous surgery and/or irradiation and who have measurable or non-measurable disease documented by CT or MRI may be eligible to participate in this trial.
Please review the detailed eligibility criteria.
Eligible patients can find the nearest participating institution online or by contacting the Southwest Oncology Group at (210) 614-8808 or at protocols@swog.org.
|
|
|
|
 |
|
